Found 286 articles for: "biologics"
Secukinumab: Long-term Safety and Efficacy in Psoriasis
August 2017 | Volume 16 | Issue 8 | Supplement Individual Articles | 115 | Copyright © August 2017
Psoriasis Is a Chronic Disease: Long Term Efficacy and Safety of New Biologics Is Important
August 2017 | Volume 16 | Issue 8 | Supplement Individual Articles | 113 | Copyright © August 2017
Increased understanding of psoriasis has led to a shift in treatments from non-specific immunosuppressants to targeted biologics. Studies in psoriasis have demonstrated minimal risk and substantial...
Read MoreEfficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study
August 2017 | Volume 16 | Issue 8 | Original Article | 801 | Copyright © August 2017
INTRODUCTION: Many options are available for patients with moderate to severe plaque psoriasis. Patients with moderate disease, however, are often undertreated and do not achieve satisfactory clear...
Read MoreAdalimumab in Chronic Plaque Psoriasis: A Clinical Guide
August 2017 | Volume 16 | Issue 8 | Original Article | 779 | Copyright © August 2017
Psoriasis is a common, inflammatory disease that manifests itself as lesions on the skin, which greatly impacts the physical and psychological wellbeing of those affected. The current goal of treat...
Read MoreTreatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation
August 2017 | Volume 16 | Issue 8 | Original Article | 760 | Copyright © August 2017
Inverse or intertriginous psoriasis commonly involves skin fold areas including the axillae, perianal skin, intergluteal cleft, inframammary, genital/inguinal, abdominal, and retroauricular folds. ...
Read MoreMethods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results
August 2017 | Volume 16 | Issue 8 | Original Article | 734 | Copyright © August 2017
BACKGROUND: An issue in long-term clinical trials of biologics in psoriasis is how to handle missing efficacy data. This methodological challenge may not be understood by clinicians, yet can have a...
Read MoreA Major Win for the Treatment of Nail Psoriasis
August 2017 | Volume 16 | Issue 8 | Editorials | 731 | Copyright © August 2017
Despite mounting evidence that biologics provide the fastest and most efficacious for nail psoriasis, it remains challenging for patients to get access to these medications, often requiring concomitan...
Read MoreDrivers of Healthcare Costs Among the Costliest Patients With Psoriasis Over Three Years in a United States Health Plan
July 2017 | Volume 16 | Issue 7 | Original Article | 651 | Copyright © July 2017
OBJECTIVE: To compare patients with psoriasis by cost level over 3 years.
METHODS: Psoriasis patients in a large US health plan in 2011-2013 were identified. Four groups were created by h...
Read MoreA Survey Assessment of US Dermatologists’ Perception of Biosimilars
June 2017 | Volume 16 | Issue 6 | Original Article | 612 | Copyright © June 2017
BACKGROUND: Biologics have transformed the treatment of psoriasis and psoriatic arthritis, but at a significant cost to payers and patients. The introduction of biosimilars into the US market could...
Read MoreA Systematic Review of Light Emitting Diode (LED) Phototherapy for Treatment of Psoriasis: An Emerging Therapeutic Modality
May 2017 | Volume 16 | Issue 5 | Original Article | 482 | Copyright © May 2017
Background: Psoriasis is a chronic, inflammatory skin condition. The economic burden of psoriasis is approximately $35.2 billion in the United States per year, and treatment costs are increasing at...
Read MoreThe Current State of Dermatologists’ Familiarity and Perspectives of Biosimilars for the Treatment of Psoriasis: A Global Cross-Sectional Survey
April 2017 | Volume 16 | Issue 4 | Original Article | 336 | Copyright © April 2017
BACKGROUND: Biologic patent expiration, accelerated approval pathways, and business interests of third party payers and the biopharmaceutical industry are driving the development of biosimilars to ...
Read MoreTwo Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis
March 2017 | Volume 16 | Issue 3 | Original Article | 234 | Copyright © March 2017
BACKGROUND: A novel lotion formulation of halobetasol propionate, 0.05% (HBP Lotion) with enhanced vehicle characteristics of a cream while preserving the ease of use and cosmetic elegance of a lot...
Read MoreDermatologists: Collaborating With Payers to Optimize Coverage Policies
March 2017 | Volume 16 | Issue 3 | Original Article | 228 | Copyright © March 2017
Dermatologists are frustrated by payer constraints that limit their ability to optimize patient treatment. They can benefit from understanding the payer formulary process and places in that process wh...
Read MorePatient Preference for Dosing Frequency Based on Prior Biologic Experience
March 2017 | Volume 16 | Issue 3 | Original Article | 220 | Copyright © March 2017
Background: There is limited research exploring patient preferences regarding dosing frequency of biologic treatment of psoriasis. Methods: Patients with moderate-to-severe plaque psoriasis identifie...
Read MoreUse of Biologics in Private Practice: Nine Years of Lessons and Learning
March 2017 | Volume 16 | Issue 3 | Original Article | 215 | Copyright © March 2017
Over a decade ago, the FDA approved biologics for psoriasis, which changed how the disease is treated and, in most cases, has a significant positive impact on the lives of patients. Side effects p...
Read MoreA Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis
March 2017 | Volume 16 | Issue 3 | Original Article | 197 | Copyright © March 2017
BACKGROUND: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Treatment options focus on r...
Read MoreEvaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2
February 2017 | Volume 16 | Issue 2 | Original Article | 147 | Copyright © February 2017
BACKGROUND: The Physician Global Assessment and Body Surface Area (PGAxBSA) composite tool is a simple, effective alternative for measuring psoriasis severity. OBJECTIVE: To evaluate the product of P...
Read MoreThe International Dermatology Outcome Measures (IDEOM) Initiative: A Review and Update
February 2017 | Volume 16 | Issue 2 | Original Article | 119 | Copyright © February 2017
The International Dermatology Outcome Measures (IDEOM) group, comprising patients, physicians, health economists, industry partners, payers, and regulatory agencies, was established to develop unif...
Read MoreHarnessing the Power of Nitric Oxide for Therapeutic Application in Dermatology
January 2017 | Volume 16 | Issue 1 | Supplement Individual Articles | 3 | Copyright © January 2017
Does Increasing the Dose of Abobotulinumtoxina Impact the Duration of Effectiveness for the Treatment of Moderate to Severe Glabellar Lines?
December 2016 | Volume 15 | Issue 12 | Original Article | 1544 | Copyright © December 2016
OBJECTIVE: To evaluate the duration of effect of a single dose of 120 units of abobotulinumtoxinA for the treatment of moderate to severe glabellar lines. DESIGN: Investigator-initiated, prospectiv...
Read More